These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32469067)

  • 1. Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease.
    Noureldin M; Cohen-Mekelburg S; Mahmood A; Stidham R; Higgins PDR; Govani S; Deshpande AR; Waljee AK
    Inflamm Bowel Dis; 2021 Mar; 27(4):516-521. PubMed ID: 32469067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
    Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
    J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
    van Staa TP; Card T; Logan RF; Leufkens HG
    Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
    Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
    Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
    [No Abstract]   [Full Text] [Related]  

  • 5. No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study.
    Jairath V; Hokkanen SRK; Guizzetti L; Boxall N; Campbell-Hill S; Patel H
    Aliment Pharmacol Ther; 2019 Aug; 50(4):416-424. PubMed ID: 31298421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    Bernstein CN; Nugent Z; Blanchard JF
    Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International variation in medication prescription rates among elderly patients with inflammatory bowel disease.
    Benchimol EI; Cook SF; Erichsen R; Long MD; Bernstein CN; Wong J; Carroll CF; Frøslev T; Sampson T; Kappelman MD
    J Crohns Colitis; 2013 Dec; 7(11):878-89. PubMed ID: 23018106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease.
    Yao LY; Shao BL; Tian F; Ye M; Li YQ; Wang XL; Wang L; Yang SQ; Lv XP; Jia Y; Wang XH; Zhang XQ; Wei YL; Cao Q
    World J Gastroenterol; 2022 Aug; 28(30):4102-4119. PubMed ID: 36157116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.
    Gjuladin-Hellon T; Gordon M; Iheozor-Ejiofor Z; Akobeng AK
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008414. PubMed ID: 31220875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
    Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
    Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
    Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
    Mahmud N; Weir DG; Kelleher D
    Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study.
    Chhaya V; Saxena S; Cecil E; Subramanian V; Curcin V; Majeed A; Pollok RC
    Aliment Pharmacol Ther; 2016 Sep; 44(5):482-94. PubMed ID: 27375210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?
    Elseviers MM; D'Haens G; Lerebours E; Plane C; Stolear JC; Riegler G; Capasso G; Van Outryve M; Mishevska-Mukaetova P; Djuranovic S; Pelckmans P; De Broe ME;
    Clin Nephrol; 2004 Feb; 61(2):83-9. PubMed ID: 14989626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia.
    Selinger CP; Kemp A; Leong RW
    Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):329-34. PubMed ID: 24490626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.
    Ma C; Ascoytia C; McCarrier KP; Martin M; Feagan BG; Jairath V
    Dig Dis Sci; 2018 Oct; 63(10):2555-2563. PubMed ID: 29959726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.
    Walker AM; Szneke P; Bianchi LA; Field LG; Sutherland LR; Dreyer NA
    Am J Gastroenterol; 1997 May; 92(5):816-20. PubMed ID: 9149192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
    Atia O; Goren I; Fischler TS; Weisband YL; Greenfeld S; Kariv R; Ledderman N; Matz E; Rimon RM; Dotan I; Turner D; Yanai H
    Aliment Pharmacol Ther; 2023 May; 57(9):1004-1013. PubMed ID: 36894866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.
    Schoepfer AM; Bortolotti M; Pittet V; Mottet C; Gonvers JJ; Reich O; Fournier N; Vader JP; Burnand B; Michetti P; Froehlich F
    Aliment Pharmacol Ther; 2014 Oct; 40(8):930-7. PubMed ID: 25146487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.